Glycemic variability (OR 2.13) and systemic immune-inflammation index (OR 1.81) were independent risk factors for atrial fibrillation in T2DM patients, with their combination yielding an AUC of 0.812.
Cohort (n=1,436)
Are glycemic variability and systemic immune-inflammation index associated with the occurrence of atrial fibrillation in patients with type 2 diabetes mellitus?
The combination of glycemic variability and systemic immune-inflammation index provides superior diagnostic performance for identifying high risk of atrial fibrillation in patients with type 2 diabetes.
Effect estimate: OR 2.13 (GV), OR 1.81 (SII) (95% CI 1.57-2.93 (GV), 1.25-2.62 (SII))
p-value: p=<0.01
PURPOSE: This study aimed to investigate the association of glycemic variability (GV) and the systemic immune-inflammation index (SII) with atrial fibrillation (AF) in patients with type 2 diabetes mellitus (T2DM). METHODS: In this retrospective study of 1436 T2DM patients, we used multivariable logistic regression and restricted cubic splines (RCS) in the derivation cohort to assess the associations of GV and SII with AF. Robustness was tested via sensitivity and subgroup analyses, while the combined model's discriminative performance was evaluated using receiver operating characteristic curves, interaction analysis, integrated discrimination improvement (IDI), and net reclassification improvement (NRI). The model subsequently underwent external validation in the validation cohort, where its calibration and discrimination were assessed. Finally, decision curve analysis (DCA) was employed to determine its clinical utility. RESULTS: In the derivation cohort, multivariable logistic regression confirmed GV (OR: 2.13, 95% CI: 1.57-2.93; P < 0.01) and SII (OR: 1.81, 95% CI: 1.25-2.62; P < 0.01) as independent risk factors for AF, with RCS analyses revealing significant nonlinear relationships. The robustness of these associations was supported by consistent results in subgroup and sensitivity analyses. The combined GV-SII model demonstrated significantly discriminatory power than either marker alone (AUC, GV: 0.709; SII: 0.753; combined: 0.812), reflected by marked improvements in both the NRI and integrated discrimination improvement. DCA further affirmed the clinical utility of the combined model. All key findings were successfully replicated in an external validation cohort. CONCLUSIONS: Both GV and SII demonstrate significant discriminative value for the occurrence of AF in T2DM patients, and their combination yields superior diagnostic performance, enabling the identification of high-risk individuals.
Zeng et al. (Fri,) conducted a cohort in Type 2 diabetes mellitus (T2DM) (n=1,436). Glycemic variability (GV) and systemic immune-inflammation index (SII) was evaluated on Atrial fibrillation (AF) (OR 2.13 (GV), OR 1.81 (SII), 95% CI 1.57-2.93 (GV), 1.25-2.62 (SII), p=<0.01). Glycemic variability (OR 2.13) and systemic immune-inflammation index (OR 1.81) were independent risk factors for atrial fibrillation in T2DM patients, with their combination yielding an AUC of 0.812.